NetworkNewsBreaks – ContraFect Corp. (NASDAQ: CFRX) Featured in Mizuho Securities Research Report
ContraFect Corp. (NASDAQ: CFRX) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “ContraFect released 4Q20 earnings that were essentially a non-event, as is often the case for a clinical-stage company. The company's recent BARDA contract and equity raise solidifies its capital position and adds external credibility to the exebacase program. Attention now shifts back to the DISRUPT trial, with interim data expected in 2H 2021 and final data in 2022. We maintain our 70% POS for DISRUPT at the final analysis given the strength of the Phase 2 exebacase data in…







